Inclusion Criteria:

- diagnosis of adenocarcinoma of the stomach

- Stage IV disease not amenable to curative surgery.

- Disease status must be that of measurable disease as defined by RECIST criteria

- Performance Status of 0 or 1 on the ECOG Scale and adequate organ function.

- Signed informed consent from patient

Exclusion Criteria:

- Prior palliative chemotherapy for advanced disease.

- Known or suspected brain metastasis or Second primary malignancy that is clinically
detectable at the time of consideration for study enrollment.

- Concurrent administration of any other tumor therapy

- Inability to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs)
2 days before, the day of, and 2 days after the dose of ALIMTA plus cisplatin.

- Inability or unwillingness to take folic acid, vitamin B12 supplementation, or
dexamethasone.